Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.
about
Gastrointestinal cancers in the era of theranostics: Updates and future perspectivesManagement of patients with hepatic metastases from neuroendocrine tumorsFavourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumoursStreptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment StratificationThe assessment of Ki-67 as a prognostic marker in neuroendocrine tumours: a systematic review and meta-analysis.Solid neuroendocrine breast carcinoma: mammographic and sonographic features in thirteen cases.Surgical resection improves the outcome of the patients with neuroendocrine tumor liver metastases: large data from AsiaEpidemiological features of gastroenteropancreatic neuroendocrine tumors in Chengdu city with a population of 14 million based on data from a single institution.Real-world study of everolimus in advanced progressive neuroendocrine tumors.Expression of IMP3 as a marker for predicting poor outcome in gastroenteropancreatic neuroendocrine neoplasms.Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel.Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.Duodenal gangliocytic paraganglioma showing lymph node metastasis: a rare case report.Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.Gastric neuroendocrine tumours.The role of chemotherapy and/or octreotide in patients with metastatic gastroenteropancreatic and hepatobiliary neuroendocrine carcinomaSearching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: Evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA octreotide SPECT/CTBilocal recurrence of a neuroendocrine carcinoma of the small intestine: A case report.Transplantation and surgical strategies in patients with neuroendocrine liver metastases: protocol of four systematic reviews.Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumoursA clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report.Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors.Natural history and outcome in Chinese patients with gastroenteropancreatic neuroendocrine tumours: - a 17-year retrospective analysisAggressive Locoregional Treatment Improves the Outcome of Liver Metastases from Grade 3 Gastroenteropancreatic Neuroendocrine TumorsGene Expression of Glucose Transporter 1 (GLUT1), Hexokinase 1 and Hexokinase 2 in Gastroenteropancreatic Neuroendocrine Tumors: Correlation with F-18-fluorodeoxyglucose Positron Emission Tomography and Cellular Proliferation.Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study.The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs.A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasmsThe Clinicopathologic Features and Treatment of 607 Hindgut Neuroendocrine Tumor (NET) Patients at a Single Institution.Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.Sequelae and survivorship in patients treated with (131)I-MIBG therapyClinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database.Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis.Histological characterisation and prognostic evaluation of 62 gastric neuroendocrine carcinomas.Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors.May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET? A pilot report on (188)Re-HEDP treatment in progressive bone metastases after (177)Lu-octreotate.Early diagnosis and treatment of gastrointestinal neuroendocrine tumors.A woman with metastatic pancreatic neuroendocrine tumor.
P2860
Q26801215-B36CD765-58D8-4429-BDEF-01E5A15897B6Q27008832-F8F474F0-E146-4897-BFF8-FB71FE27FA0AQ28247667-C01889A0-36AE-4D96-87FA-F0F4C79073E0Q28551275-E5FC0F99-8AE5-4CCA-A82D-D7D3D164F0DBQ30252003-FBD94A01-0F10-4F4B-8744-4C5BB51D7BDFQ30445932-439A7810-AAEF-40D3-8997-042B285A9F08Q30884528-8F76FF0E-4D35-43EE-88E1-E307E06CFDBDQ31095566-F0EFD00C-EAA6-4415-AD75-75FC76C8841DQ33417013-D1799D83-BFC7-454D-8570-85B5DA62AFC7Q33598498-1B75F830-C422-432A-9913-27D1779A6C30Q33658301-3B037A3B-AE43-4BC5-9CED-E6E1EEB3B505Q33782024-9B381294-12C6-4BC7-96D5-E4706E897518Q33783119-201C0D08-BC45-4332-BDBD-185E579AF1FEQ33870146-DAE1B466-6CC8-46B6-9C0B-8918697EED6CQ33901099-24483B72-227A-4996-851B-BFCCF4867E1DQ34248487-98490515-55CC-41AA-8C0B-8782D8FC56C5Q34306680-14B9CF73-18CB-4918-A887-751DA85909CEQ34484273-09619787-6B5E-405C-AAA8-AEA2DEC0D10EQ34503869-A2156C08-16DF-43ED-9BEE-617FD4C40603Q34768375-BC0173F7-B689-46EB-B14F-5839DA17D739Q35074937-FBF17B07-500B-4CB9-8618-82BAA03A1194Q35274974-83E5FC88-30B0-4C3D-BB05-81AEA1A8FBE9Q35284530-3B3CE48C-0C3D-43FA-AE38-1A4BE9583A52Q35895493-ED85A461-FAEB-4B63-97B8-6071FC430DB5Q35934630-796C705F-45C5-40F4-B1E5-C01CA497BF02Q36153131-9C1E1385-95A5-4953-9D86-2DD6E46128BBQ36335121-9B603EBA-694C-404D-BAF9-05AF4EB5E371Q36344419-D3ECDD25-D7F1-4B72-AE44-F02BEA643CEDQ36657306-CC7E5CA6-9C86-4943-ACD3-3F67679CE473Q36857533-E4EEFB19-B686-4F31-B0F9-E73BD8801314Q36993386-4EAD3A7B-BF7C-42F4-9F0A-99DE2B631B40Q37056120-0B2FE9A6-9851-499A-B719-79B42AB03C45Q37081870-4B6C9D7B-27D9-43EB-8965-F9DC0A4418C8Q37085554-B36BE781-CCF7-4B9A-A6F7-DC330AAD7A70Q37201458-EC2C3B58-361F-4F87-82E8-DB9F824684D3Q37274363-8859AD85-2683-4F2D-8E88-0234C87CD67BQ37358231-1A0F3CC3-FA9B-4248-AFAD-7DB8F4922923Q37402627-4F3F981B-E2AB-4938-8549-39EA74A11E5AQ37406973-160F4BC2-B105-4FCC-A288-C3C8852690CFQ37584857-8C0EF3AD-2EA7-4758-B27A-D7336A805328
P2860
Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.
@en
Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.
@nl
type
label
Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.
@en
Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.
@nl
prefLabel
Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.
@en
Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.
@nl
P2093
P356
P1476
Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.
@en
P2093
Bertram Wiedenmann
Martin Koch
Michael Böhmig
Stefan N Willich
Stephanie Roll
Ulrich-Frank Pape
Uta Berndt
P304
P356
10.1677/ERC-08-0017
P577
2008-07-04T00:00:00Z